References
- ROZLYTREK® Summary of Product Characteristics, 2020.
- Bergethon K, et al. J Clin Oncol 2012;30:863–870.
- Dugay F, et al. Oncotarget 2017;8:53336–53351.
- Patil T, et al. J Thorac Oncol 2018;13:1717–1726.
- Amatu A, Sartore-Bianchi A, Siena S. ESMO Open 2016;1:e000023.
- Lange AM, Lo HW. Cancers (Basel) 2018;10.
- Vaishnavi A, Le AT, Doebele RC. Cancer Discov 2015;5:25–34.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for details on how to report adverse reactions.
© 2021. RF. Hoffmann-La Roche Ltd.
M-XX-00003955 Date of preparation: July 2021
This site is intended for those outside the United States.